Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Approvals Action
MSD facing $26m diabetes challenge
MSD has seen the first rival brands registered against its top-selling gliptin, Januvia while GSK has won approval of an HSA-free version of Varilix.
Special Report
Would pharmacy deregulation make a difference?
What if the government accepts the Harper review recommendation and scraps pharmacy location and ownership rules? Would it be so bad?
Open Forum
Exclusive Q&A with new Bayer boss Nelson Ambrogio
Nelson Ambrogio became Bayer's new country representative for Australia at the start of this month. In this exclusive Q&A he talks to Pharma in Focus about the core issues for his company and the industry, and tells some of his own story.
Pipeline Monitor
Antidote in view for remaining NOACs
An antidote to novel oral anticoagulants Eliquis and Xarelto is expected to be filed by year end while Shire has won a priority FDA review for dry eye treatment lifitegrast.
Working Life
What pharma staff say about HR
Who is HR looking after, you or the company you work for? Your responses to our latest industry survey show opinions vary significantly on HR's function and performance.